888-969-2592
Kalkine 0
countryflagCA

Bausch + Lomb Corp

Healthcare CA BLCO

19.56CAD
0.27(1.40%)

Last update at 2025-07-10T17:20:00Z

Day Range

19.2019.60
LowHigh

52 Week Range

14.5629.37
LowHigh

Fundamentals

  • Previous Close 19.29
  • Market Cap5841.65M
  • Volume536
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA562.00M
  • Revenue TTM4829.00M
  • Revenue Per Share TTM13.71
  • Gross Profit TTM 2899.00M
  • Diluted EPS TTM-1.4

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 73.00M 318.00M 290.00M 399.00M 417.00M
Minority interest -9.00000M -11.00000M -1.00000M -5.00000M -
Net income 15.00M 182.00M -17.00000M 298.00M 710.00M
Selling general administrative 1478.00M 1389.00M 1253.00M 1382.00M -
Selling and marketing expenses - - - - -
Gross profit 2249.00M 2298.00M 2127.00M 2451.00M 2352.00M
Reconciled depreciation 244.00M 415.00M 442.00M 469.00M -
Ebit 207.00M 329.00M 260.00M 532.00M 416.00M
Ebitda 457.00M 785.00M 750.00M 1001.00M 932.00M
Depreciation and amortization 250.00M 456.00M 490.00M 469.00M 516.00M
Non operating income net other - - - - -
Operating income 207.00M 329.00M 260.00M 532.00M 416.00M
Other operating expenses 3548.00M 3419.00M 3114.00M 3315.00M 3238.00M
Interest expense 146.00M 63.00M 19.00M 138.00M 29.00M
Tax provision 58.00M 125.00M 307.00M 96.00M -
Interest income 6.00M 0.00000M 3.00M 1.00M -
Net interest income -140.00000M 0.00000M 3.00M 1.00M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 58.00M 125.00M 307.00M 96.00M -302.00000M
Total revenue 3768.00M 3765.00M 3412.00M 3778.00M 3665.00M
Total operating expenses 2029.00M 1952.00M 1829.00M 1988.00M 1925.00M
Cost of revenue 1519.00M 1467.00M 1285.00M 1327.00M 1313.00M
Total other income expense net -134.00000M -11.00000M 30.00M -133.00000M 1.00M
Discontinued operations - - - - -
Net income from continuing ops 15.00M 193.00M -17.00000M 303.00M -
Net income applicable to common shares 6.00M 182.00M -18.00000M 298.00M -
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 13469.00M 13442.00M 11144.00M 10823.00M 11266.00M
Intangible assets 3494.00M 3589.00M 2058.00M 2264.00M 2562.00M
Earning assets - - - - -
Other current assets 410.00M 541.00M 431.00M 168.00M 155.00M
Total liab 6925.00M 6522.00M 4043.00M 1421.00M 1278.00M
Total stockholder equity 6473.00M 6850.00M 7033.00M 9329.00M 9918.00M
Deferred long term liab - - - - -
Other current liab 403.00M 400.00M 901.00M 860.00M 731.00M
Common stock - - - 10364.00M 10807.00M
Capital stock 0.00000M 0.00000M 0.00000M 10364.00M 10807.00M
Retained earnings -571.00000M -254.00000M 6.00M - -
Other liab - - 244.00M 230.00M 286.00M
Good will 4523.00M 4575.00M 4507.00M 4586.00M 4685.00M
Other assets - - 1023.00M 1001.00M 1101.00M
Cash 305.00M 331.00M 354.00M 174.00M 238.00M
Cash and equivalents - - - - -
Total current liabilities 1738.00M 1579.00M 1296.00M 1099.00M 909.00M
Current deferred revenue - 627.00M - - -
Net debt 4479.00M 4231.00M 2082.00M -174.00000M -238.00000M
Short term debt - 30.00M 25.00M - -
Short long term debt 40.00M 30.00M 25.00M - -
Short long term debt total - 4562.00M 2436.00M - -
Other stockholder equity - 8349.00M 8285.00M -1035.00000M -889.00000M
Property plant equipment - - 1419.00M 1337.00M 1264.00M
Total current assets 2788.00M 2742.00M 2137.00M 1635.00M 1654.00M
Long term investments - - - - -
Net tangible assets - - 468.00M 2479.00M 2671.00M
Short term investments - - - - -
Net receivables 1026.00M 839.00M 724.00M 721.00M 645.00M
Long term debt 4744.00M 4532.00M 2411.00M - -
Inventory 1036.00M 1028.00M 628.00M 572.00M 616.00M
Accounts payable 389.00M 522.00M 370.00M 239.00M 178.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -1245.00000M -1258.00000M -1035.00000M -889.00000M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 294.00M 225.00M 215.00M 180.00M 165.00M
Deferred long term asset charges - - - - -
Non current assets total 10681.00M 10700.00M 9007.00M 9188.00M 9612.00M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -215.00000M -214.00000M -256.00000M -186.00000M -
Change to liabilities 189.00M 163.00M -144.00000M 78.00M -
Total cashflows from investing activities -215.00000M -214.00000M -256.00000M -186.00000M -
Net borrowings 2458.00M 28.00M 28.00M 28.00M -
Total cash from financing activities 81.00M -712.00000M -232.00000M -606.00000M -665.00000M
Change to operating activities -7.00000M -13.00000M 40.00M -6.00000M -
Net income 15.00M 193.00M -17.00000M 303.00M 719.00M
Change in cash 203.00M -61.00000M 46.00M 4.00M 16.00M
Begin period cash flow 177.00M 238.00M 192.00M 188.00M 172.00M
End period cash flow 380.00M 177.00M 238.00M 192.00M 188.00M
Total cash from operating activities 345.00M 873.00M 522.00M 799.00M 763.00M
Issuance of capital stock - - - - -
Depreciation 379.00M 415.00M 442.00M 469.00M 495.00M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -106.00000M -15.00000M -32.00000M -91.00000M -7.00000M
Change to account receivables -95.00000M -107.00000M 77.00M -21.00000M -9.00000M
Sale purchase of stock - - - - -
Other cashflows from financing activities 94.00M -712.00000M -232.00000M -606.00000M -665.00000M
Change to netincome -21.00000M 248.00M 157.00M 72.00M -
Capital expenditures 175.00M 209.00M 259.00M 180.00M 101.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -19.00000M 28.00M -59.00000M -40.00000M -78.00000M
Stock based compensation 62.00M 62.00M 50.00M 50.00M 43.00M
Other non cash items -2.00000M 59.00M 9.00M 56.00M 28.00M
Free cash flow 170.00M 664.00M 263.00M 619.00M 662.00M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BLCO
Bausch + Lomb Corp		 0.27 1.40% 19.56 - 21.98 1.21 0.67 1.84 17.69

Reports Covered

Stock Research & News

View All

Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Bausch + Lomb Corp

520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4

Key Executives

Name Title Year Born
Mr. Joseph C. Papa CEO & Director 1956
Mr. Osama A. Eldessouky Exec. VP & CFO 1972
Ms. Christina M. Ackermann Exec. VP, Gen. Counsel & Pres of Ophthalmic Pharmaceuticals 1965
Mr. Joseph F. Gordon Pres of Global Consumer, Surgical & Vision Care 1965
Ms. Kelly Webber Exec. VP & Chief HR Officer NA
Dr. Yehia Hashad M.D. Exec. VP of R&D and Chief Medical officer 1967
Mr. Louis W. Yu Exec. VP & Chief Quality Officer 1950
Mr. Dennis Asharin Exec. VP and Chief Global Manufacturing & Supply Chain Officer NA
Mr. Brenton L. Saunders J.D. CEO & Chairman 1970
Mr. Osama A. Eldessouky Executive VP & CFO 1972

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.